Novartis stocks continue to attract interest as various firms, including Harrell Investment Partners, Kingstone Capital Partners, Sovran Advisors, Scharf Investments and others, increase their stakes. The Analysts maintain a
'Hold' rating on Novartis AG and the company maintains momentum after the Sandoz spin-off.
UBS also reaffirms their hold rating, however, Goldman Sachs recommended a
'Sell' suggesting the stock is overvalued. Notably, Novartis completed its acquisition of both
Regulus Therapeutics for $1.7 billion and
Tourmaline Bio in a $1.4 billion deal. It also signed a $5.7B licensing deal with
Monte Rosa, leading to a surge in Monte Rosa's shares. At the same time, Novartis announced a $10 billion stock buyback after a strong Q2 performance. Despite concerns about the impact of Trump's tariffs on the pharmaceutical sector, Novartis stated that the new U.S. pharmaceutical tariff should not affect them due to their US investments. There are speculations about a potential deal with
Avidity and rumors of a Novartis takeover of a small biotech company. The firm also expects good growth from the moonshot cancer therapy.
Novartis Stocks News Analytics from Thu, 03 Apr 2025 07:00:00 GMT to Sat, 27 Sep 2025 20:44:36 GMT -
Rating 2
- Innovation -2
- Information 8
- Rumor 3
